. Author manuscript; available in PMC: 2022 Nov 17.

Published in final edited form as: Cancer Cell. 2022 Oct 27;40(11):1374–1391.e7. doi: 10.1016/j.ccell.2022.10.001

Table 1.

Comparison of models based on the BIC method

		Pre-treatment tumor area			Post-treatment LA
		CD66b⁺Gr (TAN)	M1 TAM	M2 TAM	CD8⁺ T cell	CD8⁺GZMB⁺ T cell

GVAX + Nivo Arm	survival (day)
	OS	10.16^b	16.51	16.19	11.71^a	15.21
	DFS	12.40	12.93	14.10	14.53	14.61
	distance (μm)
	tumor to CD8⁺ cell	129.34	129.17	129.36	128.87	123.73^b
	tumor to CD8⁺PD-1⁺ cell	141.94	141.87	142.02	141.22	136.96^b
	tumor to CD8⁺PD-1⁻ cell	95.43	93.73	94.15	94.94	87.93^b
	tumor to CSF1R⁺ cell	125.93	124.72	125.97	126.04	124.43
	tumor to PD-L1⁺CSF1R⁺ cell	139.21	137.86	139.20	139.25	137.85
	tumor to PD-L1⁻CSF1R⁺ cell	79.02	79.50	79.47	79.12	75.49^a
	PD-L1⁺CSF1R⁺ cell to CD8⁺PD-1⁺ cell	114.26	113.34	112.57	114.11	108.80^b
GVAX Arm	survival (day)
	OS	6.55	6.91	6.64	8.74^a	12.99
	DFS	7.12	6.43	6.65	11.04	9.23
	distance (μm)
	tumor to CD8⁺ cell	49.21	49.21	49.21	85.23	80.03^b
	tumor to CD8⁺PD-1⁺ cell	52.88	52.88	52.88	91.72	88.03^a
	tumor to CD8⁺PD-1⁻ cell	44.14	44.14	44.14	74.82	66.83^b
	tumor to CSF1R⁺ cell	47.38	47.38	47.38	94.36	95.24
	tumor to PD-L1⁺CSF1R⁺ cell	50.85	50.85	50.85	102.98	104.36
	tumor to PD-L1⁻CSF1R⁺ cell	41.56	41.56	41.56	70.91	66.81^a
	PD-L1⁺CSF1R⁺ cell to CD8⁺PD-1⁺ cell	49.77	49.77	49.77	84.28	83.14

LA, lymphoid aggregate; OS, overall survival; DFS, disease-free survival; TAN, tumor-associated neutrophil; M1 TAM, M1-like tumor-associated macrophage; M2 TAM, M2-like tumor-associated macrophage.

Considered to have a meaningful difference.

Considered to have a strong difference.